Neuron23 Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $96.5M

  • Investors
  • 14

Neuron23 General Information

Description

Developer of precision medicines designed to treat genetically defined neurological, immunological, and inflammatory diseases. The company offers human genetics-based drug discovery, biomarker development, machine learning technologies, artificial intelligence-driven research capabilities, and therapeutic development programs, enabling patients with neurodegenerative, neuroinflammatory, autoimmune, and inflammatory diseases to access targeted treatment approaches.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 343 Oyster Point Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 343 Oyster Point Boulevard
  • Suite 120
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuron23 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 24-Jun-2025 $96.5M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 30-Mar-2022 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 15-Dec-2020 $80M $113M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 18-Oct-2018 $33.5M $33.5M Completed Stealth
To view Neuron23’s complete valuation and funding history, request access »

Neuron23 Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B
Series A-2 19,885,000 $0.000100 $0.08 $1.03 $1.03 1x $1.03 7.23%
Series A-1 13,000,000 $0.000100 $0.08 $1 $1 1x $1 4.73%
To view Neuron23’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neuron23 Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision medicines designed to treat genetically defined neurological, immunological, and inflammatory dis
Drug Discovery
South San Francisco, CA
27 As of 2026

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neuron23 Competitors (5)

One of Neuron23’s 5 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Casma Therapeutics Venture Capital-Backed Cambridge, MA
Beam Therapeutics Formerly VC-backed Cambridge, MA
Abeona Therapeutics Corporation Cleveland, OH
Denali Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 5 competitors. Get the full list »

Neuron23 Patents

Neuron23 Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025264994-A1 Predictive biomarkers and use thereof to treat parkinson's disease Pending 21-Jun-2024
WO-2025194074-A1 Kinase modulators and methods of use thereof Pending 15-Mar-2024
WO-2025137541-A1 Kinase modulators and methods of use thereof Inactive 22-Dec-2023
AU-2024269632-A1 Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 Pending 11-May-2023
EP-4709377-A2 Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 Pending 11-May-2023 C12Q1/6883
To view Neuron23’s complete patent history, request access »

Neuron23 Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuron23 Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Blue Owl Capital Asset Manager Minority
Chimera Capital PE/Buyout Minority
SoftBank Investment Advisers Growth/Expansion Minority
Acorn Bioventures Venture Capital Minority
Cowen Healthcare Investments Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Neuron23 FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process